CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Methylprednisolone Acetate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2021-12-15. Latest FDA row update: 2026-10-02.
FDA lists 23 package records, with companies: Amneal Pharmaceuticals, Amneal Pharmaceuticals LLC, Eugia US LLC, Par Health, USA LLC, Pfizer Inc., Pharmacia & Upjohn Company LLC, Sagent Pharmaceuticals. Package NDCs: 0009-0274-01, 0009-0280-02, 0009-0280-03, 0009-0280-51, 0009-0280-52, 0009-0306-02, 0009-0306-12, 0009-3073-01, 0009-3073-03, 0009-3073-22, 0009-3073-23, 0009-3475-01, 0009-3475-03, 25021-820-05, 25021-820-10, 25021-821-05, 42023-240-01, 55150-313-01, 55150-314-01, 70121-1573-1, 70121-1573-5, 70121-1574-1, 70121-1574-5.
FDA shortage reason: Demand increase for the drug; Other; Shortage of an active ingredient
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Amneal Pharmaceuticals | 70121-1573-1 | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1) | Limited Availability | 2026-06-17 |
| Amneal Pharmaceuticals | 70121-1573-5 | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5) | Available | 2026-06-17 |
| Amneal Pharmaceuticals | 70121-1574-1 | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1) | Available | 2026-06-17 |
| Amneal Pharmaceuticals | 70121-1574-5 | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5) | Available | 2026-06-17 |
| Eugia US LLC | 55150-313-01 | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01) | Unavailable | 2026-10-02 |
| Eugia US LLC | 55150-314-01 | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01) | Unavailable | 2026-10-02 |
| Par Health, USA LLC | 42023-240-01 | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01) | Unavailable | 2026-10-02 |
| Pfizer Inc. | 0009-0274-01 | Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01) | Available | 2026-09-21 |
| Pfizer Inc. | 0009-0280-02 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02) | Available | 2026-09-21 |
| Pfizer Inc. | 0009-0280-03 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03) | Limited Availability | 2026-09-21 |
| Pfizer Inc. | 0009-0280-51 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51) | Available | 2026-09-21 |
| Pfizer Inc. | 0009-0280-52 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52) | Available | 2026-09-21 |
| Pfizer Inc. | 0009-3073-01 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01) | Limited Availability | 2026-09-21 |
| Pfizer Inc. | 0009-3073-03 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03) | Limited Availability | 2026-09-21 |
| Pfizer Inc. | 0009-3073-22 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22) | Unavailable | 2026-09-21 |
| Pfizer Inc. | 0009-3073-23 | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23) | Unavailable | 2026-09-21 |
| Pfizer Inc. | 0009-0306-02 | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02) | Available | 2026-09-21 |
| Pfizer Inc. | 0009-0306-12 | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12) | Available | 2026-09-21 |
| Pfizer Inc. | 0009-3475-01 | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01) | Limited Availability | 2026-09-21 |
| Pfizer Inc. | 0009-3475-03 | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03) | Limited Availability | 2026-09-21 |
| Sagent Pharmaceuticals | 25021-820-05 | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05) | Unavailable | 2026-09-18 |
| Sagent Pharmaceuticals | 25021-820-10 | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10) | Unavailable | 2026-09-18 |
| Sagent Pharmaceuticals | 25021-821-05 | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05) | Limited Availability | 2026-09-18 |
Source facts
Grouped generic ingredient: Methylprednisolone Acetate Injection · 23 package records
Therapeutic categories: Rheumatology
Dosage forms: Injection
Routes: INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.